Pioneering Neuroprotection and Regeneration for Neurodegenerative Diseases and Disorders


Genervon is a closely held, clinical-stage biopharmaceutical company focused on novel treatments for neurodegenerative diseases and disorders, for which no effective therapy has been developed to date.  Genervon believes that the key to the successful treatment of these conditions is to address their common underlying pathophysiology through a master regulatory approach.

In 1996, Genervon discovered what it believes is the naturally occurring regulator of the development of the human nervous system, called the “motoneuronotrophic factor” (MNTF).  Following a multi-year research and drug development effort, Genervon has advanced GM6, a 6-amino-acid active analog peptide of MNTF, into Phase 2 clinical development. 

Genervon holds more than 80 patents worldwide for MNTF, GM6 and related compounds and processes and is currently planning late-stage clinical trials for GM6 for ALS, PD, AD and MS indications.



Recognizing the lack of curative therapies for patients suffering from neurodegenerative diseases and disorders, Genervon has devoted the last twenty years to research and development in pursuit of a cure. 



Genervon’s innovation is in using a master regulatory approach to target the common underlying pathophysiology of neurodegenerative diseases and disorders and their multiple  pathways and genes. 


What's New

After 20 years of funding its own research and operations, Genervon is now actively seeking partners to help advance GM6 from a development-stage drug candidate to a marketable therapy for the many victims of neurodegenerative diseases and disorders that desperately need help.